Peptides in 2TM · Tirzepatide

Tamer Coskun, Kyle W. Sloop and their colleagues published tirzepatide’s discovery and early human proof-of-concept work in 2018. This is a team attribution, not a sole-inventor claim. The authentic Lilly headquarters photograph illustrates corporate location context; it does not identify the exact room or laboratory where the medicine was created.

Tirzepatide is one engineered peptide that activates GIP and GLP-1 receptors. Its C20 fatty diacid enables albumin binding and prolonged circulation. The receptor art illustrates separate interactions of copies of the medicine, not one molecule spanning two receptors, equal potency at both receptors, or a verified atom-level binding pose. The tissue cutaway compresses time and uses illustrative scale; it is not an injection guide. Gastric-emptying delay is greatest after the first dose and diminishes over time.

SURMOUNT-1 enrolled 2,539 adults with obesity, or overweight plus at least one weight-related complication, excluding diabetes. The randomized, double-blind, placebo-controlled trial included lifestyle intervention and 72 weeks of treatment, including escalation. The treatment-regimen estimand assessed outcomes regardless of treatment discontinuation. Mean weight changes were −15.0% with 5 mg, −19.5% with 10 mg, −20.9% with 15 mg and −3.1% with placebo. The film selects the 15 mg/placebo comparison as a study result, not a dose recommendation, individual prediction or cross-trial superiority claim.

First U.S. Mounjaro approval was May 13, 2022; initial EU Mounjaro authorization followed September 15, 2022. U.S. Zepbound weight-management approval followed November 8, 2023. The current U.S. Mounjaro label includes type 2 diabetes treatment in adults and children aged 10 and above, plus major cardiovascular event risk reduction in adults with type 2 diabetes at high risk; the latter indication was added in August 2026. The current U.S. Zepbound label includes eligible adult weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. EU Mounjaro includes diabetes and eligible adult weight management. These regional examples are not a complete worldwide approval or supply inventory; local labels, access and funding differ.

The film provides selected safety information. Common gastrointestinal effects include nausea, vomiting and diarrhea. Important warnings and restrictions include pancreatitis, gallbladder disease, severe gastrointestinal reactions, dehydration-related kidney injury, hypersensitivity and hypoglycemia with certain diabetes medicines; relevant labels also discuss retinopathy and aspiration during anesthesia or deep sedation. U.S. labels contraindicate use with personal or family medullary thyroid carcinoma, MEN2 or serious hypersensitivity. Thyroid C-cell tumors occurred in rats; human relevance is unknown. The short film cannot reproduce every warning, interaction or pregnancy consideration; consult the full applicable label and a clinician.

Evidence cutoff: October 12, 2026. Source verification is distinct from scientific assessment or personal human review; no independent human scientific review is claimed. Self-reported observations remain distinct from clinical research and do not establish safety or effectiveness. WPF does not sell peptides or provide medical advice.

• Coskun, Sloop and colleagues: discovery and early human proof of concept, 2018
• Jastreboff and colleagues, NEJM: SURMOUNT-1, 2022
• SURMOUNT-1 trial registration
• Current U.S. Mounjaro prescribing information
• Current U.S. Zepbound prescribing information
• EMA Mounjaro assessment and product information
• FDA original Mounjaro approval, May 13, 2022
• FDA Zepbound weight-management approval, November 8, 2023

Images, music & reuse rights

Headquarters photograph: Paul Sableman, February 16, 2011, Lilly headquarters, CC BY 2.0; cropped and composited with WPF titles. No endorsement implied. Retain attribution and the changes notice when republishing.

Eight seconds of public-domain CDC laboratory automation footage provide general context, not Lilly production or SURMOUNT-1 footage. The source depicts SARS-CoV-2 antibody testing in 2020. CDC provides source details and identifies its government-produced B-roll as public domain in its B-roll reuse guidance. Courtesy: CDC; no endorsement implied.

Six new AI-created artworks show membrane/receptor environments, separate organs, subcutaneous tissue, chromatography and an explicitly unbranded vial. They are conceptual educational illustrations, not patient imaging, verified molecular structures, actual Lilly facilities or authentic branded product photographs. Narration and music are synthetic. Montserrat is used under the SIL Open Font License.

Educational information, not medical advice. Suggest a correction.